Table 2.
Patient baseline characteristics.
| Factors | Unmatched | Matched | ||||
|---|---|---|---|---|---|---|
| B-I (n=95) | Non-B-I (n=150) | P | B-I (n=59) | Non-B-I (n=59) | P | |
| Gender | 0.336 | 0.285 | ||||
| Male | 76 (80.00%) | 112 (74.67%) | 47 (79.66%) | 42 (71.19%) | ||
| Female | 19 (20.00%) | 38 (25.33%) | 12 (20.34%) | 17 (28.81%) | ||
| Age (y) | 0.021* | 1.000 | ||||
| ≤65 | 51 (53.68%) | 58 (38.67%) | 25 (42.37%) | 25 (42.37%) | ||
| >65 | 44 (46.32%) | 92 (61.33%) | 34 (57.63%) | 34 (57.63%) | ||
| NRS 2002 score | 0.071 | 0.567 | ||||
| 1-2 | 72 (75.79%) | 93 (62.00%) | 41 (69.49%) | 38 (64.41%) | ||
| 3-4 | 19 (20.00%) | 44 (29.33%) | 15 (25.42%) | 15 (25.42%) | ||
| 5-6 | 4 (4.21%) | 13 (8.67%) | 3 (5.08%) | 6 (10.17%) | ||
| ASA grade | 0.900 | 0.831 | ||||
| 1-2 | 76 (80.00%) | 119 (79.33%) | 45 (76.27%) | 44 (74.58%) | ||
| 3-4 | 19 (20.00%) | 31 (20.67%) | 14 (23.73%) | 15 (25.42%) | ||
| Hypertension | 0.133 | 0.334 | ||||
| Yes | 29 (30.53%) | 60 (40.00%) | 23 (38.98%) | 18 (30.51%) | ||
| No | 66 (69.47%) | 90 (60.00%) | 36 (61.02%) | 41 (69.49%) | ||
| Diabetes mellitus | 0.101 | 0.499 | ||||
| Yes | 14 (14.74%) | 35 (23.33%) | 11 (18.64%) | 14 (23.73%) | ||
| No | 81 (85.26%) | 115 (76.67%) | 48 (81.36%) | 45 (76.27%) | ||
| Previous abdominal surgery | 0.515 | 0.071 | ||||
| Yes | 10 (10.53%) | 20 (13.33%) | 5 (8.47%) | 13 (22.03%) | ||
| No | 85 (89.47%) | 130 (86.67%) | 54 (91.53%) | 46 (77.97%) | ||
| Tumor location | <0.001* | 1.000 | ||||
| Cardia | 0 (0.00%) | 38 (25.33%) | 0 (0.00%) | 2 (3.39%) | ||
| body | 83 (87.37%) | 68 (45.33%) | 50 (84.75%) | 48 (81.36%) | ||
| Antrum | 10 (10.53%) | 37 (24.67%) | 9 (15.25%) | 7 (11.86%) | ||
| Total | 1 (1.05%) | 7 (4.67%) | 0 (0.00%) | 2 (3.39%) | ||
| Differentiated degree | 0.237 | 0.972 | ||||
| Differentiated | 69 (72.63%) | 117 (78.00%) | 41 (69.49%) | 40 (67.8%) | ||
| Undifferentiated | 8 (8.42%) | 16 (10.67%) | 7 (11.86%) | 7 (11.86%) | ||
| Signet ring carcinoma | 18 (18.95%) | 17 (11.33%) | 11 (18.64%) | 12 (20.34%) | ||
| Pathological type | 0.883 | 0.113 | ||||
| Ulcerative type | 83 (87.37%) | 132 (88.00%) | 51 (86.44%) | 56 (94.92%) | ||
| Non-ulcerative type | 12 (12.63%) | 18 (12.00%) | 8 (13.56%) | 3 (5.08%) | ||
| TNM stage | <0.001* | 0.833 | ||||
| I | 50 (52.63%) | 32 (21.33%) | 19 (32.2%) | 16 (27.12%) | ||
| II | 20 (21.05%) | 43 (28.67%) | 15 (25.42%) | 16 (27.12%) | ||
| III | 25 (26.32%) | 75 (50.00%) | 25 (42.37%) | 27 (45.76%) | ||
| Combined organ resection | 0.004* | 1.000 | ||||
| Yes | 1 (1.05%) | 16 (10.67%) | 1 (1.69%) | 1 (1.69%) | ||
| No | 94 (98.95%) | 134 (89.33%) | 58 (98.31%) | 58 (98.31%) | ||
| Laparoscopic gastrectomy | 0.001* | 1.000 | ||||
| Yes | 33 (34.74%) | 24 (16.00%) | 13 (22.03%) | 13 (22.03%) | ||
| No | 62 (65.26%) | 126 (84.00%) | 46 (77.97%) | 46 (77.97%) | ||
BMI body mass index, ASA American Society of Anesthesiologists, NRS 2002 nutritional risk screening 2002, TNM tumor-node-metastasis.
The values given are number of patients and values in parentheses are percentages.-
*Represent P < 0.05, which was considered to be statistically significant.